These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23504536)

  • 21. In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis.
    Ge F; Zeng F; Liu S; Guo N; Ye H; Song Y; Fan J; Wu X; Wang X; Deng X; Jin Q; Yu L
    J Med Microbiol; 2010 May; 59(Pt 5):567-572. PubMed ID: 20075118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Direct nitrate reductase method of assessment of Mycobacterium tuberculosis susceptibility to drug].
    Poliakov AE; Mazurova IK
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (5):94-6. PubMed ID: 18041125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol.
    Dickinson JM; Mitchison DA
    Tubercle; 1976 Dec; 57(4):251-8. PubMed ID: 827836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular mechanisms of mycobacterium tuberculosis strains resistance to rifampicin and isoniazid].
    Stepanshina VN; Panfertsev EA; Mitrofanova GN; Korobova OV; Stepanshin IuG; Shemiakin IG; Medvedeva IM
    Probl Tuberk; 2000; (1):32-6. PubMed ID: 10750428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Commercial Kit SIRE Nitratase for detecting resistant Mycobacterium tuberculosis in Brazil.
    Miranda SS; Almeida IN; Lopes ML; Figueiredo JDR; Figueredo LJA; Kritski AL; Carvalho WDS; Mansur MFFO
    Rev Soc Bras Med Trop; 2017; 50(4):550-553. PubMed ID: 28954080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of the resazurin microtitre assay for detection of multidrug resistance in Mycobacterium tuberculosis in Algiers.
    Nateche F; Martin A; Baraka S; Palomino JC; Khaled S; Portaels F
    J Med Microbiol; 2006 Jul; 55(Pt 7):857-860. PubMed ID: 16772411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.
    Kasule GW; Kateete DP; Joloba ML
    BMC Infect Dis; 2016 Apr; 16():173. PubMed ID: 27097724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Typing of Mycobacterium tuberculosis strains resistant to rifampicin and isoniazid by molecular biological methods.
    Skotnikova OI; Nosova EY; Markova OV; Irtuganova OA; Krudu VN; Ginda SS; Golishcheva OV; Biryukova MN; Strel'tsova EN; Kalyanina OV; Litvinov VI; Moroz AM; Lapa SA; Gryadunov DA; Mikhailovich VM
    Bull Exp Biol Med; 2003 Sep; 136(3):273-5. PubMed ID: 14666192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of individual drugs in the chemotherapy of tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 2000 Sep; 4(9):796-806. PubMed ID: 10985648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Quantitative analysis of sigma genes expression in Mycobacterium tuberculosis cultures exposed to rifampicin and isoniazid].
    Pendzich J; Maksymowicz-Mazur W; Mazurek U; Dworniczak S; Oklek K; Kozielski J; Wilczok T
    Wiad Lek; 2004; 57(5-6):233-40. PubMed ID: 15518067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis.
    Mohammadzadeh A; Farnia P; Ghazvini K; Behdani M; Rashed T; Ghanaat J
    J Med Microbiol; 2006 Dec; 55(Pt 12):1657-1659. PubMed ID: 17108268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
    Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
    J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
    Imperiale BR; Di Giulio ÁB; Adrián Cataldi A; Morcillo NS
    J Antibiot (Tokyo); 2014 Nov; 67(11):749-54. PubMed ID: 24894185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing antimycobacterial activity of isoniazid and rifampicin incorporated norbornene nanoparticles.
    Kumarasingam K; Vincent M; Mane SR; Shunmugam R; Sivakumar S; Uma Devi KR
    Int J Mycobacteriol; 2018; 7(1):84-88. PubMed ID: 29516891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method.
    Walters SB; Hanna BA
    J Clin Microbiol; 1996 Jun; 34(6):1565-7. PubMed ID: 8735121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant prevention concentration of isoniazid, rifampicin and rifabutin against Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; Ruiz M; López M; Royo G
    Chemotherapy; 2005 May; 51(2-3):76-9. PubMed ID: 15870500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial.
    Abdelaal A; El-Ghaffar HA; Zaghloul MH; El Mashad N; Badran E; Fathy A
    Ann Clin Microbiol Antimicrob; 2009 Jan; 8():4. PubMed ID: 19183459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Description of Mycobacterium tuberculosis mutations conferring resistance to rifampicin and isoniazid detected by GenoType® MTBDRplus V.2 in Colombia].
    Llerena C; Medina R
    Biomedica; 2017 Jan; 37(1):28-33. PubMed ID: 28527245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The occurrence and frequency of genomic mutations that mediate Isoniazid and Rifampicin resistance in
    Kumwenda GP; Chipungu G; Sloan DJ; Kaimila Y; Chiumya K; Pangani H
    Malawi Med J; 2018 Mar; 30(1):1-5. PubMed ID: 29868151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.